Table 3.

Comparison of endogenous levels of oxylipins in human plasma and serum determined by our method with those previously reported measurement [47–4,9, 66–6,9]

Compound	Current work*1	Reported in Ref [66]a	Reported in Ref [48]b	Reported in Ref [65]c	Reported in Ref [47]d	Reported in Ref [49]e	Reported in Ref [67]f	Current work*2	Reported in Ref [68]g	Reported in Ref [47]d	Reported in Ref [69]h
	Plasma concentration (ng/mL)							Serum concentration (ng/mL)
9-HODE	0.667–5.28	0.865–4.132	27.20		11.961–20.776	0–26.969		2.80–5.64	0.744–3.270	14.05–21.43	1.748 ±0.151
13-HODE	0.506–6.76	1.286–5.826	38.30		9.933–19.933	0–21.094		1.72–9.67	1.290–8.370	11.93–24.61	2.281 ±0.178
9-oxoODE	NQ-0.578		4.11					0.23–0.53
13-oxoODE	NQ-0.755	0.347–2.136	2.05					0.39–0.87	0–1.270
9,10-EpOME	NQ-0.772	0.308–1.368	0.06					NQ-2.08	0^4.500		1.688 ±0.195
12,13-EPOME	NQ −11.6	0.181–0.684	0.07					2.82–7.63	4.230–23.90		1.925 ± 0.190
9,10-DiHOME	0.304–3.13	0.644–2.130	0.10					0.59–1.00	0.221–1.730		1.100 ± 0.167
12,13-DiHOME	0.238–2.88	1.053–3.739	0.09					0.77–2.45	0.536–2.630		1.948 ± 0.151
9,12,13-TriHOME	NQ-2.24*	0.168–0.429						−	0.218–0.932
9,10,13-TriHOME	NQ*	0.248–0.528						−	0.047–0.257
9,10,11-TriHOME	ND*							−
9-HOTrE	NQ-0.212							0.10–0.24			0.118 ±0.012
13-HOTrE	NQ-0.452		1.38					0.20–0.47			0.115 ±0.011
PGE2	NQ	0.053–0.106	0.07	0.029 ±0.013	NQ	NQ		NQ-0.54	0.043–0.462	0.135–0.454
PGF2α	NQ	0.078–0.184	NQ	<0.05	0.175–0.533	NQ		NQ-0.70	0.231–6.090	0.210–0.537
8-IsoPGF2α	NQ		NQ	0.052 ±0.026	0.162–0.567	NQ		NQ		NQ
TXB2	NQ-0.249	0.096–0.481	NQ	0.179 ±0.065	0.057–0.324	NQ		0.12–68.10	0.108–37.10	0.908–4.762
LTB4	NQ		0.55	<0.01	0.284–0.552	NQ		0.20–0.71	0.008–0.213	0.282–0.544
LXA4	NQ		0.15	0.016±0.019	NQ	NQ		NQ		0.251–0.738
LXB4	NQ		0.26		0.284–0.553	NQ		NQ		1.020–1.519
5-HETE	0.127–0.866	0.026–0.138	16.66	0.399 ±0.148	0.287–0.529	0.442–0.707		1.09–2.10	0.158–0.569	0.613–0.993	0.512 ±0.042
8-HETE	NQ-0.265	0.022–0.090	1.52	0.280 ±0.092	0.041–0.075			0.25–1.28	0–21.200	0.003–0.291	0.112 ±0.004
9-HETE	NQ-0.182	0–0.032	3.13	0.328±0.122		NQ		NQ −0.45			0.054 ± 0.003
11-HETE	NQ-0.270	0.019–0.102	2.54	0.316 ± 0.148	0.110–0.166	0.172–0.284		0.25^.78	0.036–1.050	0.160–0.381	0.179 ±0.023
12-HETE	NQ-0.627	0.051–0.416	2.87	3.12 ±2.502	0.260–0.482	NQ		8.9–524.00	2.610–38.60	0.912–4.610	4.963 ± 0.929
15-HETE	NQ-0.614	0.061–0.311	3.39	1.307 ±0.356	0.268–0.532	0.435–0.756		0.54–6.65	0.182–1.80	0.396–0.497	0.352 ± 0.035
20-HETE	NQ-0.761	0.016–0.118	NQ	1.308 ±0.212		NQ		0.74–1.46	0–1.900
5-oxoETE	NQ-0.247	0–0.051			0.263–0.388	NQ		0.10–0.18		NQ
5,6-EET	NQ	0–019-0.096			0.109–0.195	NQ		NQ	0.333–1.820	NQ
8.9-EET	NQ	0.006–0.054	NQ	0.147±0.104	0.181–0.346	NQ		NQ-0.70	0.109–0.791	NQ	0.202 ± 0.020
11,12-EET	NQ	0–0.058	NQ	0.165 ±0.225	NQ	NQ		NQ-0.21	0.191–0.870	NQ	0.448 ± 0.045
14,15-EET	NQ	0–0.026	NQ	0.125 ± 0.136	NQ	0.188–0.220		0.15–0.30	0.081–0.803	NQ	0.416 ± 0.042
18-HEPE	NQ						0.068–0.119	0.11–0.30
14(15)-EEQ	NQ		NQ					NQ			0.067 ± 0.008
17(18)-EEQ	NQ		NQ					NQ			0.102 ±0.009
4-HDHA	NQ-0.114		2.73					0.15–0.35
7-HDHA	NQ		0.13					NQ −0.15
10-HDHA	NQ		0.20					NQ
14-HDHA	NQ-0.659		0.56		0.237–1.415		0.169–0.780	2.65–71.4		0.400–1.314
17-HDHA	NQ-0.387	0–0.145 0.40	0–0.145 0.40		0.227–0.670		0.047–0.157	0.23–3.48		0.029–0.513
PDX	NQ				0.591–1.718			NQ		NQ
MaR1	NQ					NQ		NQ
RvD1	NQ		NQ		NQ	NQ	0.028–0.568	NQ	0–0.51	NQ
RvD2	NQ				NQ		0.047–0.084	NQ	0–0.470	NQ
16,17-EDP	NQ		NQ					NQ			0.165 ±0.018
19(20)-EDP	NQ-0.243		NQ					0.16–0.31			0.379 ± 0.038

NQ: not quantifiable, the concentration is below the LOQ or out of the linear range or not detected from the matrix, −: not quantified

^*1:n = 40,

^*2n = 5,

^*n = 4

^aEicosanoid profiles in control human plasma (n = 3), concentrations were converted from nM reported in the article to ng/mL

^bEicosanoid profiles in control human plasma (mean value, n = 3)

^cEicosanoid profiles in human plasma from healthy volunteers (n = 6)

^dEicosanoid profiles in non-fasting control human plasma (n = 9)

^eEicosanoid profiles in control human plasma (n = 50)

^fEicosanoid profiles in control human plasma (n = 21)

^gEicosanoid profiles in control human serum (n = 16)

^hOxylipin profiles in control human plasma (n = 20), concentrations were converted from pM (±SE) reported in the article to ng/mL (±SE)